Table 1.
Baseline Characteristics.
| Character | Total, n. (%) | Fruquintinib group, n. (%) | Regorafenib group, n. (%) | p-value |
|---|---|---|---|---|
| Patients | 105 | 55 | 50 | |
| Sex | 0.965 | |||
| Male | 80 (76.2) | 42 (76.4) | 38 (76.0) | |
| Female | 25 (23.8) | 13 (23.6) | 12 (24.0) | |
| Age (years, median (range)) | 62 (32-78) | 61 (32-78) | 63 (41-78) | 0.246 |
| Age | 0.794 | |||
| <65 years | 56 (53.3) | 30 (54.5) | 26 (52.0) | |
| ≥65 years | 49 (46.7) | 25 (45.5) | 24 (48.0) | |
| Baseline ECOG PS | 0.196 | |||
| 0 | 40 (38.1) | 24 (43.6) | 16 (32.0) | |
| 1 | 45 (42.9) | 19 (34.5) | 26 (52.0) | |
| 2 | 20 (19.0) | 12 (21.8) | 8 (16.0) | |
| Primary tumor location at first diagnosis | 0.236 | |||
| Center | 79 (75.2) | 44 (80.0) | 35 (70.0) | |
| Right | 26 (24.8) | 11 (20.0) | 15 (30.0) | |
| Primary disease site at first diagnosis | 0.751 | |||
| Colon | 55 (52.4) | 28 (50.9) | 27 (54.0) | |
| Rectum | 50 (47.6) | 27 (49.1) | 23 (46.0) | |
| Multiple metastases at study entry | ||||
| Lung | 66 (62.9) | 38 (69.1) | 28 (56.0) | 0.166 |
| Liver | 72 (68.6) | 39 (70.9) | 33 (66.0) | 0.588 |
| Peritoneum | 29 (27.6) | 11 (20.0) | 18 (36.0) | 0.067 |
| Bone | 24 (22.9) | 14 (25.5) | 10 (20.0) | 0.506 |
| Number of metastases sites at treatment start | 0.111 | |||
| <3 | 63 (60.0) | 29 (52.7) | 34 (68.0) | |
| ≥3 | 42 (40.0) | 26 (47.3) | 16 (32.0) | |
| MSI status | 0.963 | |||
| pMMR | 93 (88.6) | 49 (89.1) | 45 (90.0) | |
| dMMR | 4 (3.8) | 2 (3.6) | 2 (4.0) | |
| Unknown | 7 (6.7) | 4 (7.3) | 3 (6.0) | |
| RAS mutation status | 0.872 | |||
| RAS wild type | 48 (45.7) | 24 (43.6) | 24 (48.0) | |
| RAS mutant | 49 (46.7) | 27 (49.1) | 22 (44.0) | |
| Unknown | 8 (7.6) | 4 (7.3) | 4 (8.0) | |
| BRAF V600E status | 0.513 | |||
| Wild-type | 93 (88.6) | 50 (90.9) | 43 (86.0) | |
| Mutation | 4 (3.8) | 1 (1.8) | 3 (6.0) | |
| Unknown | 8 (7.6) | 4 (7.3) | 4 (8.0) | |
| Prior antitumor treatment | 0.787 | |||
| Radical surgery | 70 (66.7) | 38 (69.1) | 32 (64.0) | |
| Non-radical surgery | 5 (4.8) | 2 (1.8) | 3 (6.0) | |
| Chemotherapy or Radiation therapy | 30 (28.6) | 15 (27.3) | 15 (30.0) | |
| Prior chemotherapy with VEGF and EGFR inhibitors | 0.479 | |||
| Neither | 12 (11.4) | 4 (7.3) | 8 (16.0) | |
| VEGF inhibitor | 84 (80.0) | 46 (83.6) | 38 (76.0) | |
| EGFR inhibitor | 24 (22.9) | 14 (25.5) | 10 (20.0) | |
| Both | 15 (14.3) | 9 (16.4) | 6 (12.0) | |
| Combination of PD-1 inhibitors | 0.666 | |||
| with | 59 (56.2) | 32 (58.2) | 27 (54.0) | |
| without | 46 (43.8) | 23 (41.8) | 23 (46.0) | |
ECOG PS, Eastern Cooperative Oncology Group performance status; MSI, microsatellite instability, pMMR, proficient mismatch repair; dMMR, different Mismatch Repair; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; PD-1, programmed death receptor-1.